ALPINE IMMUNE SCIENCES, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 13 rows in 2022. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2022-08-17: Reporting owner Sandler Andrew Seth; Form 4; Security Stock Option (Right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-07-18: Reporting owner Drappa Jorn; Form 4; Security Stock Option (Right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-07-15: Reporting owner Venkatesan Jay; Form 4; Security Stock Option (Right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2022-01-04: Reporting owner PENG STANFORD L; Form 4; Security Stock Option (Right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2022-08-17 | Sandler Andrew Seth Officer (Chief Medical Officer) | 4 | Stock Option (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +160,000 160,000 owned after | $8.38 exercise price | 2022-08-18 | |
| 2022-07-18 | Drappa Jorn Director | 4 | Stock Option (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $8.71 exercise price | 2022-07-19 | |
| 2022-07-15 | Venkatesan Jay Director, 10% Owner | 4 | Stock Option (Right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,063 70,000 owned after | $0.45 | 2022-07-19 | |
| 2022-01-04 | PENG STANFORD L Officer (See Remarks) | 4 | Stock Option (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +215,000 215,000 owned after | $13.30 exercise price | 2022-01-06 | |
| 2022-01-04 | GOLD MITCHELL Director, Officer (Executive Chairman and CEO), 10% Owner | 4 | Stock Option (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +215,000 215,000 owned after | $13.30 exercise price | 2022-01-06 | |
| 2022-01-04 | Rickey James Paul Officer (Senior VP and CFO) | 4 | Stock Option (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +112,500 112,500 owned after | $13.30 exercise price | 2022-01-06 | |
| 2022-01-03 | Venkatesan Jay Director, 10% Owner | 4 | Stock Option (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $13.89 exercise price | 2022-01-04 | |
| 2022-01-03 | Peetz Christopher Director | 4 | Stock Option (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $13.89 exercise price | 2022-01-04 | |
| 2022-01-03 | CONWAY ROBERT E Director | 4 | Stock Option (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $13.89 exercise price | 2022-01-04 | |
| 2022-01-03 | Topper James N Director, 10% Owner | 4 | Stock Option (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $13.89 exercise price | 2022-01-04 | |
| 2022-01-03 | Hernday Natasha Director | 4 | Stock Option (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $13.89 exercise price | 2022-01-04 | |
| 2022-01-03 | Thompson Peter A. Director, 10% Owner | 4 | Stock Option (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $13.89 exercise price | 2022-01-04 | |
| 2022-01-03 | Cui Xiangmin Director, 10% Owner | 4 | Stock Option (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $13.89 exercise price | 2022-01-04 |